Prot #LP0162-1326: A randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab monotherapy in subjects with moderate-to-severe atopic dermatitis who are candidates for systemic therapy

  • Silverberg, Jonathan I (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date11/9/17 → 11/9/20

Funding

  • LEO Pharma A/S (Prot #LP0162-1326)